Ligand Pharmaceuticals Inc. (LGND) announced on Monday that it has agreed to purchase Apeiron Biologics AG, a private biopharmaceutical company located in Vienna, Austria for $100 million in cash. This acquisition will grant Ligand the royalty rights to Apeiron's Qarziba, the sole immunotherapy for high-risk neuroblastoma, available in 35 countries in Europe and other global regions.

配体制药公司（LGND）周一宣布，已同意以1亿美元现金收购位于奥地利维也纳的私营生物制药公司Apeiron Biologics AG。此次收购将授予Ligand对Apeiron的Qarziba的专利权，Qarziba是高风险神经母细胞瘤的唯一免疫疗法，可在欧洲和其他全球地区的35个国家获得。

In addition to the initial amount, Ligand will compensate Apeiron shareholders based on upcoming commercial and regulatory milestones, potentially reaching up to $28 million if Qarziba royalties surpass specific thresholds by 2030 or 2034. .

除初始金额外，Ligand还将根据即将到来的商业和监管里程碑向Apeiron股东提供补偿，如果Qarziba特许权使用费在2030年或2034年超过特定阈值，则可能达到2800万美元。

Simultaneously, Ligand will engage in a stock purchase agreement, committing to invest up to $4 million in invIOs Holding AG, a privately owned spin-off of Apeiron to support the research and development of three new early-stage immuno-oncology assets, with Apeiron entitled to royalties and milestone payments on these assets.

同时，Ligand将签署一份股票购买协议，承诺向invIOs Holding AG投资高达400万美元，invIOs Holding AG是Apeiron的私有分拆公司，用于支持三项新的早期免疫肿瘤学资产的研究和开发，Apeiron有权获得这些资产的版税和里程碑付款。

The transaction is anticipated to close in July 2024. For comments and feedback contact: editorial@rttnews.comBusiness News.

该交易预计于2024年7月完成。如需评论和反馈，请联系：editorial@rttnews.comBusiness新闻。

Biotech Stocks Facing FDA Decision In June 2024

2024年6月美国食品和药物管理局（FDA）决定生物技术股

Biotech Stocks Facing FDA Decision In April 2024

2024年4月美国食品和药物管理局（FDA）决定生物技术股

Biotech Stocks Facing FDA Decision in March 2024

2024年3月美国食品和药物管理局（FDA）决定生物技术股